Registration for PeproTech.com is no longer available. To order your PeproTech products online, register or logon to ThermoFisher.com.

Resources & Support

References

First Author
Wang, W
Title
Hepatobiliary Tumor Organoids Reveal HLA Class I Neoantigen Landscape and Antitumoral Activity of Neoantigen Peptide Enhanced with Immune Checkpoint Inhibitors.
Citation
Advanced science (Weinheim, Baden-Wurttemberg, Germany); 2022 Aug; 9(22) pge2105810
PubMed ID
35665491
Show Usages
Product Cited
Cross-Reactivity
Applications
200-02
Human
in vitro
200-07
Human
in vitro
200-15
Human
in vitro
First Author
Hebbar, N
Title
CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells.
Citation
Nature communications; 2022 Jan 31; 13(1) pg587
PubMed ID
35102167
Show Usages
Product Cited
Cross-Reactivity
Applications
200-07
Human
in vitro
200-15
Human
in vitro
First Author
Banskota, S
Title
Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins.
Citation
Cell; 2022 Jan 20; 185(2) pg250-265.e16
PubMed ID
35021064
Show Usages
Product Cited
Cross-Reactivity
Applications
200-02
Human
in vitro
200-07
Human
in vitro
200-15
Human
in vitro
First Author
Moosmann, C
Title
Orthotopic T-cell receptor replacement in primary human T cells using CRISPR-Cas9-mediated homology-directed repair.
Citation
STAR protocols; 2022 Mar 18; 3(1) pg101031
PubMed ID
34977677
Show Usages
Product Cited
Cross-Reactivity
Applications
200-15
Human
in vitro
200-07
Human
in vitro
200-02
Human
in vitro
First Author
Albanese, M
Title
Rapid, efficient and activation-neutral gene editing of polyclonal primary human resting CD4+ T cells allows complex functional analyses.
Citation
Nature methods; 2022 Jan; 19(1) pg81-89
PubMed ID
34949807
Show Usages
Product Cited
Cross-Reactivity
Applications
200-07
Human
in vitro
200-15
Human
in vitro
300-28A
Human
Chemotaxis Assay
First Author
Nesterenko, P A
Title
HLA-A∗02:01 restricted T cell receptors against the highly conserved SARS-CoV-2 polymerase cross-react with human coronaviruses.
Citation
Cell reports; 2021 Dec 28; 37(13) pg110167
PubMed ID
34919800
Show Usages
Product Cited
Cross-Reactivity
Applications
200-02
Human
in vitro
200-15
Human
in vitro
First Author
Deng, B
Title
Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL.
Citation
Molecular therapy. Methods & clinical development; 2021 Dec 10; 23 pg633-643
PubMed ID
34901308
Show Usages
Product Cited
Cross-Reactivity
Applications
200-07
Human
in vitro
200-15
Human
in vitro
200-21
Human
in vitro
First Author
Nicolet, B P
Title
CD29 Enriches for Cytotoxic Human CD4+ T Cells.
Citation
Journal of immunology (Baltimore, Md. : 1950); 2021 Nov 15;
PubMed ID
34782446
Show Usages
Product Cited
Cross-Reactivity
Applications
200-15
Human
in vitro
First Author
Hirabayashi, K
Title
Dual Targeting CAR-T Cells with Optimal Costimulation and Metabolic Fitness enhance Antitumor Activity and Prevent Escape in Solid Tumors.
Citation
Nature cancer; 2021 Sep; 2(9) pg904-918
PubMed ID
34746799
Show Usages
Product Cited
Cross-Reactivity
Applications
200-07
Human
in vitro
200-15
Human
in vitro
First Author
Bent, E H
Title
Microenvironmental IL-6 inhibits anti-cancer immune responses generated by cytotoxic chemotherapy.
Citation
Nature communications; 2021 Oct 28; 12(1) pg6218
PubMed ID
34711820
Show Usages
Product Cited
Cross-Reactivity
Applications
200-10
Human
in vitro
300-23
Human
in vitro
200-12
Human
in vitro
200-15
Human
in vitro
100-20
Human
in vitro
200-06
Human
in vitro
200-06RC
Human
in vitro
showing 10 of 366
Show More